AUTOLUS THERAPEUTICS PLC - AMERICAN DEPOSITARY SHA

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

08 5 2025 06:00:01 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

25 4 2025 11:06:39 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

23 4 2025 15:05:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

22 4 2025 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

02 4 2025 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

01 4 2025 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

20 3 2025 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

06 3 2025 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Participate in Upcoming Investor Conferences

05 3 2025 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

17 1 2025 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Provides Business Updates and 2025 Overview

13 1 2025 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

09 12 2024 18:30:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

02 12 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

12 11 2024 06:00:01 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

08 11 2024 15:23:24 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

05 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

28 10 2024 16:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

16 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

19 9 2024 06:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

27 8 2024 06:00:00 提供 Nasdaq GlobeNewswire